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Abstract
Purpose. The prognosis of advanced soft tissue sarcoma is poor, only a few drugs showing some activity with response rates
around 15± 25%. Consequently drug development seems mandatory to improve treatment outcome. Following previous
favourable EORTC experience, the Italian Group on Rare Tumors started a phase II study with docetaxel to con® rm the
activity of this drug in soft tissue sarcoma.
Patients and methods. Thirty-seven patients with soft tissue sarcoma resistant to at least one anthracycline-
containing regimen were enrolled in a phase II multicenter study evaluating docetaxel 100 mg/m
2 in a 1-h i.v. infusion
q3 weeks.
Results. Thirty-seven patients were enrolled onto this phase II study and 36 were evaluable for response. Only one partial
remission was observed [2.8% with 95% con® dence interval (CI) 0.1± 16.2%]. Median progression-free and overall survival
were 42 and 350 days, respectively. Neutropenia and leukopenia as well as cutaneous manifestations were the most common
toxicities.
Discussion. The results of this phase II study do not con® rm a previous EORTC report on the activity of docetaxel in
soft tissue sarcoma, but are consistent with other more recent phase II studies. The accumulated evidence does not
justify the use of this drug in the management of patients suffering from this disease, resistant to anthracycline-
containing regimens.
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Introduction
The prognosis of advanced soft tissue sarcoma is
poor, with only three drugs, namely anthracyclines,
ifosfamide and dacarbazine, showing some activity
with a response rate of around 15± 25%.
1± 4 The
combination of such drugs does not signi® cantly
increase the response rate over single-drug
doxorubicin.
5± 9 Consequently new drug develop-
ment seems mandatory to improve the treatment
outcome of patients suffering from this disease.
Unfortunately almost all phase II studies of new
agents performed in recent years failed to show any
activity in the treatment of refractory soft tissue
sarcomas.
5,9,10
Docetaxel (Taxotere¾ ) is a semisynthetic analog of
paclitaxel derived from the needles of the European
yew, Taxus baccata. Docetaxel was shown to have
superior in vivo antitumor activity as compared to
taxol in the B16 melanoma model
11 and has shown a
favorable response rate in breast cancer.
12
A phase II study of docetaxel by the EORTC Soft
Tissue and Bone Sarcoma Group
13 reported an
overall response rate of 17% in 29 soft tissue sarcoma
patients refractory to an anthracycline-containing
regimen. According to these data, docetaxel has been
suggested as the third active agent in the treatment of
advanced soft tissue sacoma supporting its use as a
® rst-line treatment.
In September 1995, the Italian Group on Rate
Tumors started a multicenter phase II study in refrac-
tory soft tissue sarcoma to con® rm previous EORTC
experience.
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Patient population
To be eligible for the study, patients were required to
have a pathologically con® rmed diagnosis of soft tissue
sarcoma and to be resistant to at least one
anthracycline-containing regimen.
Resistance to previous chemotherapy was de® ned
as either progression during or relapse within 6
months from the end of previous chemotherapy.
Eligible patients were to have received no regimens
including docetaxel. Other inclusion criteria were as
follows: age between 16 and 65 years, ECOG
performance status £ 2, an expected survival duration
of ‡ 3 months, and previous chemotherapy completed
at least 4 weeks before study entry. Patients were
required to have bidimensionally measurable indicator
lesions, while patients with evaluable lesions alone as
well as those with pleural effusion, malignant ascites
and previously irradiated lesions were not considered
for enrollment in the study. Requirements for
eligibility also included leukocyte count ‡ 3500 cmm;
granulocyte count ‡ 1500 cmm; platelet count ‡ 100
000 cmm, and normal liver and renal function.
Patients with cardiac disease, brain metastases, other
serious medical illnesses and other malignant tumors
were excluded. Protocol and information sheet were
approved by the Scienti® c and Ethical Committee of
all the participating institutions and all patients had
to sign a written, informed consent.
Treatment plan
Before treatment, all patients had a complete history
and physical examination as well as baseline labora-
tory tests, chest X-rays, ECG, and abdominal
ultrasound. CT scan, MRI and bone scan were
performed according to the clinical indications.
Docetaxel was supplied by Rhone Poulenc Rorer
company as a concentrated sterile solution with
40 mg/ml (80 mg/2 ml, per vial) in polysorbate 80
(Tween 80). Before infusion, docetaxel was diluted in
250 ml of 5% dextrose and was given at a dose of
100 mg/m
2 i.v., over 1 h. Cycles were restarted every
21 days in the absence of toxicities requiring treat-
ment delay. Therapy was continued until disease
progression or unacceptable toxicity.
The patients did not receive anti-emetic treatment
unless the patient had experienced nausea and
vomiting with a previous dose. Pre-medication for
acute hypersensitivity reactions consisted of pred-
nisone 50 mg orally 24, 16, 8 and 1 h before and 20,
32, 44, 56, 68 and 80 h after docetaxel. Prophylactic
colony-stimulating factors were not given.Toxic effects
were reported according to the South West Oncology
Group Toxicity Criteria.
14 Dose reductions were
performed as follows: in patients with grade 3 neutro-
penia and/or grade 2 peripheral neuropathy and/or
febrile neutropenia the following cycle was lowered
of a 25%; in the absence of recovery of myelotoxicity
after 3 weeks, the subsequent dose was delayed until
toxicity resolved.
Response criteria
Response evaluation was performed every two cycles
reporting the initial parameter lesions. According to
the South West Oncology Group criteria,
14 complete
remission was de® ned as the complete disappearance
of all detectable lesions for at least 4 weeks. Partial
remission was de® ned as a ‡ 50% decrease in the sum
of the products of the diameters of measurable lesions
for at least 4 weeks, in the absence of simultaneous
increase of any lesion and/or appearance of any new
lesion. Progressive disease was de® ned as an increase
of ‡ 50% in the size of a measurable lesion or the
appearance of a new lesion. Duration of response
was determined by the interval between the day of
the ® rst treatment and the date of clear evidence of
disease progression.
Statistical analysis
The study was designed as a two-stage trial, according
to Simon’s optimal design,
15 with the following
speci® cations: a 90% probability of accepting
docetaxel for further studies was required if the true
response rate was 20% whereas the probability of
accepting it for further studies, if the true response
rate was 10%, was set at 5%.Accordingly, 12 patients
had to be entered and evaluated in the ® rst stage of
the trial. If at least one response was observed, 25
more patients had to be accrued, and, overall, at least
four responses had to be observed out of 37 patients
in order to consider the drug sufficiently active to
warrant further studies.
All patients who started the experimental treat-
ment were included in the analyses of response. All
patients in whom an objective response was not
demonstrated, including early progressions and
deaths, those who discontinued treatment due to
toxicity, and those in whom response was not evalu-
ated according to the protocol were considered as
treatment failures and included in the denominator
of the proportion of responses.
Survival and time to disease progression were evalu-
ated according to the Kaplan± Meier method.
16
Results
Patient characteristics
Between September 1995 and October 1996, 37
patients were enrolled onto this phase II study by
nine participating centres. Out of these 37 patients,
® ve were not eligible because of performance status 3
(one case), low neutrophiles <2000 cmm (two cases)
and abnormal renal function (two cases), respectively.
All patients had measurable lesions. Pre-treatment
178 A. Santoro et al.patient characteristics are listed inTable 1.The median
age was 44 years (range 20± 64 years) with a median
WHO performance status of 0 (range 0± 3). Thirty-
four patients (91.9%) presented with metastatic
disease and only three (8.1%) with locoregional
advanced disease.Twenty-four patients (64.9%) were
pre-treated with only one chemotherapy regimen, nine
(24.3%) with two, and four with four, respectively.
Previous radiotherapy had been administered to 19
patients.The histologic subtypes were as follows: leio-
myosarcoma in nine cases, synovial sarcoma in eight
cases, malignant ® brous histiocytoma and schwan-
noma in four cases, ® brosarcoma, liposarcoma and
rhabdomyosarcoma in two cases, emangiopericy-
toma and epithelioid sarcoma in one case, and unclas-
si® ed sarcoma in four cases, respectively.
Response
All 37 patients were considered evaluable for response
except one who died before starting chemotherapy. A
total of 116 cycles were administered with a median
of four courses (range 1± 8). The therapeutic results
are reported in Table 2. Only one partial response
(2.8% with a 95% con® dence interval 0.1± 16.2%)
was observed. In 10 patients, stable disease was
documented, while all other patients showed disease
progression.
The median time to progression was 42 days, and
median overall survival was 350 days, respectively
(Table 2 and Fig. 1). Death was due to tumor progres-
sion in 31 patients, to infection in one patient not
eligible because of both anemia and abnormal renal
function, and cause of death was not documented in
two cases.
Toxicity
The highest grade of toxicity according to the SWOG
Toxicity Criteria
14 for each patient is listed in Table
3. Grade 3 and 4 neutropenia and leukopenia were
the most common toxicities, while anemia and throm-
bocytopenia were rarely documented. Febrile neutro-
penia and infection were observed in a small
proportion of cases although only one patient died of
this cause. More than half of the patients developed
symptomatic rash as well as more severe cutaneous
manifestations including super® cial dry desquama-
tion of the hands and feet and dystrophic nail changes.
Hair loss was observed in almost all evaluable patients.
Vomiting and diarrhea, mucositis and neurotoxicity
were rarely reported. Fluid retention occurred in 21%
of patients but only in 6% of cases reached grade 2± 3
level and a hypersensitivity reaction was observed in
9% of cases.
Discussion
Both doxorubicin and ifosfamide have been
considered as the most active drugs in the manage-
ment of adult soft tissue sarcoma.
1± 3,5,9 Some
reports have also suggested a low level of activity of
dacarbazine.
4,9 Nonetheless the results achieved
with these drugs given alone or in combination are
poor with no clear bene® t in the advanced disease
as well as in the adjuvant setting.
1,5,9Therefore the
search for new active agents remains an important
issue. However the majority of phase II studies
failed to show any activity by almost all investigated
drugs.
1,5,9,10
The EORTC Soft Tissue and Bone Sarcoma
Group reported the results of docetaxel in previ-
ously treated soft tissue sarcoma with ® ve partial
remissions (17%) in 29 evaluable patients.
13 Based
on these positive results it was suggested that
docetaxel could be an effective drug, warranting
® rst-line phase II studies.
However, the results obtained in the present study
failed to con® rm the activity of this drug in soft tissue
sarcoma with only one partial remission in 37
anthracycline-resistant patients. Our results are in
agreement with the low response rate reported by
three studies utilizing docetaxel as ® rst-line.
17± 19
Based on our data and that of other authors, the
continued use of docetaxel for treatment of soft tissue
sarcoma is not justi® ed.
Table 1. Pretreatment patient characteristics
No. of patients entered 37
Median age in years (range) 44 (20± 64)
Sex, Males/Females 19/18
WHO performance status
Median (range) 0 (0± 3)
Site of disease
Metastatic 33 (89.2%)
Locoregional 3 (8.1%)
Both 1 (2.7%)
No of previous chemotherapy regimens
1 24 (64.9%)
2 9 (24.3%)
>2 4 (10.8%)
Previous radiotherapy 19 (51.4%)
Table 2. Response evaluation
No
Patients entered 37
Patients evaluated 36
Response
Complete 0
Partial 1 2.8%
Stable 10
Failure 25
Median duration in days
Progression-free survival 42
Overall survival 350
Deaths 36
*95% con® dence interval 0.1± 16.2%
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